[Myocardial dysfunction].
Ichihara
Kazuo
K
D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003067:Coenzymes; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000502:physiology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000145:classification / Q000627:therapeutic use*; D017682:Myocardial Stunning / Q000188:drug therapy / Q000209:etiology; D009206:Myocardium / Q000201:enzymology; D009821:Oils; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use; D012995:Solubility; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000502:physiology; D014867:Water
D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009821:Oils; D014867:Water; D014451:Ubiquinone; D019821:Simvastatin; D006903:Hydroxymethylglutaryl CoA Reductases; C024989:coenzyme Q10; D017035:Pravastatin